Biomarkers can be used in community and population studies to investigate the true prevalence of NASH and liver fibrosis.
Without treatment, liver fibrosis can progress to liver cirrhosis, liver failure, and liver cancer. Photo: Shutterstock.
The test could allow doctors to determine the stage of both fibrosis Liver disease and non-alcoholic steatohepatitis, the researchers wrote, emphasizing that this liquid biopsy test uses two circulating proteins and appears to be effective in diagnosing two important liver conditions,
The paper, authored by the team of Giulia Angelini, PhD, a postdoctoral fellow focused on the pathophysiology of non-alcoholic fatty liver disease at the Catholic University of the Sacred Heart in Rome, highlights the need for finding, according to the study published in Gut. Invasive non-targeting biomarkers.
“Diagnosis of non-alcoholic steatohepatitis (Ehna) is currently based on invasive liver biopsy.”
The research team sought to identify biomarkers and algorithms capable of predicting the presence and severity of non-alcoholic steatohepatitis.Ehna) oh so fibrosis The liver study evaluated two proteins found in circulating monocytes, a type of white blood cell: PLIN2 as a predictor of histological NASH and as a predictor of RAB14 levels fibrosis Liver.
“PLIN2 and RAB14 may allow diagnosis of NASH and/or . fibrosis liver with a simple blood test”, he wrote. “Our biomarkers can be used in community and population studies to investigate the true prevalence of Ehna You fibrosis Furthermore, since they only require a single blood sample, they are a potentially valuable tool for population and prevention studies in children.”